BioCryst to Present Research at Phoenix Allergy Meeting
The company will share four new clinical study abstracts at the American College of Allergy, Asthma and Immunology annual meeting.
Updated on Oct. 29, 2026 in Allergies
Live Poll
Do you believe clinical study updates from pharmaceutical companies help you better manage your own health?
BioCryst Pharmaceuticals will showcase four research posters regarding its hereditary angioedema therapies at the American College of Allergy, Asthma and Immunology 2026 Annual Scientific Meeting. The presentations will take place at the Phoenix Convention Center from November 12-16, 2026.
Why it matters
The company aims to provide updated insights into real-world outcomes and clinical data for its portfolio of treatments used for hereditary angioedema. This research includes findings on long-term safety, hospitalization reductions, and healthcare utilization for patients.
Researchers are presenting four specific study abstracts covering topics like dose adjustments and long-term safety profiles. The data includes analysis on the injectable inhibitor Navenibart and the oral therapy ORLADEYO, which is approved for patients aged two and older.
The players
BioCryst Pharmaceuticals
This biotechnology company focuses on the development of oral and injectable small-molecule and protein therapeutics for rare diseases.
American College of Allergy, Asthma and Immunology
This professional medical association represents thousands of allergists, immunologists, and healthcare professionals dedicated to allergy research.
The details
The presentations at the Phoenix Convention Center cover the company's hereditary angioedema portfolio through various research posters. Key topics for discussion include data on hospitalization reductions, healthcare utilization, and ongoing investigations into the dosing profiles for the monoclonal antibody Navenibart.
Timeline
November 12-16, 2026: ACAAI 2026 Annual Scientific Meeting
November 13, 2026: Poster R077 presentation at 4:20-4:35 p.m. MT
November 14, 2026: Posters R096 and R097 presentations
November 15, 2026: Poster R110 presentation at 12:00-12:15 p.m. MT
The Big Picture
This presentation aligns with the American College of Allergy, Asthma and Immunology 2026 Annual Scientific Meeting to disseminate findings to specialists. The event serves as a central hub for researchers to update the medical field on the evolution of treatments for hereditary angioedema.
Patients currently utilizing hereditary angioedema treatments may see updated clinical guidelines or safety information resulting from this research. These findings provide clarity on the effectiveness of current therapy options and the potential future availability of new injectable treatments.
The takeaway
Advancements in clinical research for hereditary angioedema are shifting toward therapies with more flexible dosing schedules. Patients and caregivers should consult with their healthcare providers to discuss how these emerging study results might influence future treatment plans.
Further reading
For more information on clinical advancements in this field, visit the Allergies section.
More information
For additional details regarding specific therapy profiles, visit the ORLADEYO patient and treatment information portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe clinical study updates from pharmaceutical companies help you better manage your own health?
